This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Aplastic and Other Anemias > Efficacy
Print

In this section:

Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC
Efficacy in Aplastic and Other Anemias

EXJADE Effectively Treats Iron Toxicity
Across Aplastic and Other Anemias

EXJADE has shown efficacy increasing the removal of excess iron in the body. In 2007, a clinical study showed patients with Diamond-Blackfan and other anemias experienced substantial iron excretion.1

EXJADE Increases Iron Excretion in Patients
With Rare Anemias1
EXJADE Increases Iron Excretion in Patients with Rare Anemias

Prospective phase 2 trial evaluating safety and efficacy of EXJADE in patients (N=184) aged 3-81 years with transfusion-dependent anemias including β-thalassemia, myelodysplastic syndrome, Diamond-Blackfan, and other
rare anemias.

Iron Excretion Increases In Patients With Other Rare Anemias

FREQUENTLY ASKED QUESTIONS ABOUT EXJADE

Answers to common
questions about many
aspects of EXJADE
therapy.

Learn more

SAFETY WITH EXJADE

Several studies have
demonstrated the
safety of EXJADE.

Learn more

Effective in reducing iron toxicity across a range of clinical parameters

Based on established testing standards, EXJADE has been shown as an effective iron chelator for those with aplastic and other anemias suffering from iron toxicity.1,2,3,4

These standards include:

  • Serum Ferritin
  • Liver Iron Concentration

EXJADE reduces iron toxicity in aplastic and other anemias

In several clinical trials, EXJADE has been shown to effectively treat iron toxicity in the following groups of anemia patients:

Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
More Information
Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC

References

  1. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
  2. Lee JW, Yoon SS, Shen ZX, Ganser A, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-54.
  3. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
  4. Data on file. Novartis Pharma AG, Basel, Switzerland.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed